- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Phase classification, Trial completion date, Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 6, 2024 P2, N=24, Recruiting, Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion, Trial completion date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Apr 18, 2023 P1/2, N=40, Completed, Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024 Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2023
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date, Metastases: ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) - Mar 2, 2023 P2/3, N=150, Not yet recruiting, Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2023 Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 1, 2023 P2b, N=24, Recruiting, Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025 Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 31, 2022 P2b, N=24, Recruiting, Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023 Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Aug 31, 2022 P1/2, N=40, Recruiting, Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment open, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 29, 2021 P2b, N=24, Recruiting, Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Jun 3, 2021 P1/2, N=40, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2022 --> Jun 2022
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 16, 2021 P2b, N=24, Not yet recruiting, Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2022 --> Jun 2022 Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 20, 2021 P2b, N=24, Not yet recruiting, Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Sep 2022
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion date, Trial primary completion date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Jan 20, 2021 P1/2, N=40, Not yet recruiting, Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Sep 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 19, 2020 P2b, N=24, Not yet recruiting, Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Mar 2022 Initiation date: Oct 2020 --> Jan 2021
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Nov 19, 2020 P1/2, N=40, Not yet recruiting, Initiation date: Oct 2020 --> Jan 2021 Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
[VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1143; Methods AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Legal entity responsible for the study: Kananathan. Funding: Has not received any funding.
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
[VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_778; AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Simple to administer, minimal side-effects and appears to have activity in refractory metastatic disease. Further controlled clinical trials is warranted.
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
[VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_404; AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Simple to administer, minimal side-effects and appears to have activity in refractory metastatic disease. Further controlled clinical trials is warranted.
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 7, 2020 P2b, N=24, Not yet recruiting, Further controlled clinical trials is warranted. Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2021
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date: ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) - Aug 7, 2020 P1/2, N=40, Not yet recruiting, Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2021 Initiation date: Jul 2020 --> Oct 2020
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
Trial completion, Phase classification, Enrollment change, Trial completion date, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Jan 22, 2020 P2a, N=15, Completed, N=25 --> 6 Recruiting --> Completed | Phase classification: P2 --> P2a | N=30 --> 15 | Trial completion date: Aug 2018 --> Mar 2019
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment change, Trial withdrawal, Metastases: AlloStim (clinicaltrials.gov) - Jan 22, 2020 P2/3, N=0, Withdrawn, Withdrawn --> Terminated; withdrawn due to poor recruitment N=450 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial completion, Phase classification, Enrollment change, Combination therapy, Metastases: AlloStim (clinicaltrials.gov) - Jan 22, 2020 P2a, N=12, Completed, N=450 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P2 --> P2a | N=18 --> 12
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
Enrollment change, Trial withdrawal, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Jan 22, 2020 P2, N=0, Withdrawn, Withdrawn --> Completed N=100 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment open, Trial primary completion date, Combination therapy, Metastases: AlloStim (clinicaltrials.gov) - Oct 21, 2016 P2, N=18, Recruiting, N=100 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial primary completion date: May 2018 --> Oct 2017
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Aug 10, 2016 P2/3, N=450, Not yet recruiting, Not yet recruiting --> Recruiting | Trial primary completion date: May 2018 --> Oct 2017 Initiation date: Dec 2016 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Jul 19, 2016 P2, N=100, Not yet recruiting, Trial primary completion date: Jul 2016 --> Dec 2016 Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Combination therapy, Metastases: AlloStim (clinicaltrials.gov) - Jul 19, 2016 P2, N=18, Not yet recruiting, Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018 Initiation date: Jun 2016 --> Sep 2016
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Apr 7, 2016 P2/3, N=450, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Phase classification, Combination therapy, Metastases: AlloStim (clinicaltrials.gov) - Apr 6, 2016 P2, N=18, Not yet recruiting, Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018 Phase classification: P2b --> P2
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Feb 24, 2016 P2, N=100, Not yet recruiting, Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Nov 2016 --> Mar 2017 Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
New P2 trial, Metastases: Study Comparing AlloVax (clinicaltrials.gov) - Dec 10, 2015 P2, N=100, Not yet recruiting,
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: AlloStim (clinicaltrials.gov) - Aug 27, 2015 P2b, N=18, Not yet recruiting, Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018 Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Aug 27, 2015 P2/3, N=450, Not yet recruiting, Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Jan 2014 --> Jan 2016 | Trial primary completion date: Jan 2016 --> Jan 2019
- |||||||||| AlloVax (CRCL/AlloStim) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) - Aug 14, 2015 P2, N=30, Not yet recruiting, Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment change, Trial withdrawal, Combination therapy: In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer (clinicaltrials.gov) - Apr 15, 2015 P1/2, N=0, Withdrawn, Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016 N=10 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Enrollment change, Trial withdrawal, Metastases: AlloStim (clinicaltrials.gov) - Apr 14, 2015 P2/3, N=0, Withdrawn, N=200 --> 0 | Not yet recruiting --> Withdrawn N=208 --> 0 | Not yet recruiting --> Withdrawn
|